FDA Denies Epix Appeal, Asks For New Vasovist Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Epix may raise the level of its appeal on the imaging agent to FDA’s Center for Drug Evaluation & Research.
You may also be interested in...
Epix Will Resubmit Vasovist NDA By Mid-Year
End appears near in long road to approval for vascular imaging agent after FDA and Epix agree on plan for Phase III study image re-reads.
Epix Will Resubmit Vasovist NDA By Mid-Year
End appears near in long road to approval for vascular imaging agent after FDA and Epix agree on plan for Phase III study image re-reads.
Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY
Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.